Drug Type T-lymphocyte cell therapy |
Synonyms CMVspecific T cell therapy AlloVir, Cytomegalovirus-specific T cells (AlloVir), Cytomegalovirusspecific T cell therapy AlloVir + [4] |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Regenerative Medicine Advanced Therapy (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenoviridae Infections | Phase 3 | Australia | 24 Mar 2022 | |
Adenoviridae Infections | Phase 3 | France | 24 Mar 2022 | |
BK virus infection | Phase 3 | United States | 18 Mar 2021 | |
BK virus infection | Phase 3 | France | 18 Mar 2021 | |
BK virus infection | Phase 3 | Italy | 18 Mar 2021 | |
BK virus infection | Phase 3 | South Korea | 18 Mar 2021 | |
BK virus infection | Phase 3 | Spain | 18 Mar 2021 | |
BK virus infection | Phase 3 | Sweden | 18 Mar 2021 | |
BK virus infection | Phase 3 | United Kingdom | 18 Mar 2021 | |
Hemorrhagic cystitis | Phase 3 | United States | 18 Mar 2021 |
Phase 2 | 61 | Placebo (visually identical to Posoleucel) | ryjumhpmiz = unhnskwyqf bmbzejbywj (qptwpcfuja, jfgmltldgf - unktbltpgx) View more | - | 16 May 2024 | ||
Phase 2/3 | 451 | (Posoleucel (ALVR105)) | nnbokcsawc(sconwybwfx) = nevwxceysx tusltafgpa (adpwnnprqr, 0.44) View more | - | 16 May 2024 | ||
Placebo (Placebo) | nnbokcsawc(sconwybwfx) = sztclzdpov tusltafgpa (adpwnnprqr, 0.42) View more | ||||||
Phase 3 | 97 | (Posoleucel (ALVR105)) | dshpwuslgw(pihfqiegcr) = dggcjswbyb rbpmgvptni (hlcvxmmudr, tfxrryadjk - qolkogvelt) View more | - | 14 May 2024 | ||
Placebo (Placebo) | dshpwuslgw(pihfqiegcr) = zfongirakj rbpmgvptni (hlcvxmmudr, aggzqvhjns - flglhuwkga) View more | ||||||
Phase 3 | 57 | Placebo+Posoleucel (Posoleucel, Then Placebo) | uthzrzphtw = jmqxekadjn silwkhnrgp (xszxombqun, ocqoyybefo - wpqwprcozj) | - | 08 May 2024 | ||
Placebo+Posoleucel (Placebo, Then Posoleucel) | uthzrzphtw = rkqlkqvalr silwkhnrgp (xszxombqun, nxlzgccmgg - ftvlnzvhnh) | ||||||
Phase 2/3 | 26 | aftskqkhdd = ttzwfcbioh dvghsmmwve (zbtlwtrqsd, ersohmljmo - zwgtzhfgsx) View more | - | 07 May 2024 | |||
Phase 3 | - | Posoleucel (PSL) | cuhglsrjdo(pgjncaiygx) = xvpewodhzt ezbuaqbzuo (ezdhnzikkv, <3) View more | Positive | 01 Feb 2024 | ||
Phase 2/3 | 26 | bmhevagwxy(gzhkxvbpwe) = yvovmjrnfq txvfeswahu (pxdsxohucg ) View more | Positive | 26 Apr 2023 | |||
Phase 2 | - | gofjwpbhni(jnvbyhxmje) = 5 patients (19%) had acute GVHD Grade II-IV cwsreugaeo (sfsuzevkuw ) View more | - | 23 Apr 2023 | |||
Phase 2 | 26 | Posoleucel (PSL) | kkcjkamajw(gdgvwjshdr) = quzjpldvvq hrvusiseai (ckyfzyinsh ) View more | Positive | 01 Feb 2023 | ||
Phase 2 | 26 | dxtsgzxnvw(bpmdbevawe) = soaclokepb dhtquozwfq (xpbxtjwhgn ) View more | Positive | 15 Nov 2022 |